Zentalis Pharmaceuticals Inc
ZNTL1.375USD
+0.035+2.61%
交易中 （美東）報價延遲15分鐘
98.93M總市值
虧損本益比TTM
關於 Zentalis Pharmaceuticals Inc 公司
Zentalis Pharmaceuticals, Inc. 是一家臨牀階段的生物製藥公司。該公司專注於發現和開發針對癌症基本生物學途徑的小分子療法。該公司的主要候選產品包括 azenosertib (ZN-c3)，這是一種用於晚期實體瘤和血液系統惡性腫瘤的 WEE1 抑制劑。該公司還在開發一種用於治療血液系統惡性腫瘤和相關疾病的 BCL-2 抑制劑 ZN-d5。ZN-d5 正在與 azenosertib 聯合使用，在 R/R 急性髓系白血病 (AML) (ZN-d5-004C) 患者的 I/II 期劑量遞增臨牀試驗中進行評估。該公司還在利用其集成發現引擎推進對蛋白質降解劑和其他未公開靶標的研究。
公司簡介
公司代碼ZNTL
公司名稱Zentalis Pharmaceuticals Inc
上市日期Apr 03, 2020
CEOMs. Julie Eastland
員工數量166
證券類型Ordinary Share
年結日Apr 03
公司地址10275 Science Center Drive
城市SAN DIEGO
上市交易所NASDAQ Global Market Consolidated
國家United States of America
郵編92121
電話18582634333
網址https://www.zentalis.com/
公司代碼ZNTL
上市日期Apr 03, 2020
CEOMs. Julie Eastland
公司高階主管
名稱
名稱/職務
職務
持股
持股變動
Mr. David Michael Johnson
Mr. David Michael Johnson
Independent Director
Independent Director
250.42K
+29.87%
Dr. Jan Skvarka, Ph.D.
Dr. Jan Skvarka, Ph.D.
Independent Director
Independent Director
194.95K
+41.94%
Dr. Enoch Kariuki, Pharm.D.
Dr. Enoch Kariuki, Pharm.D.
Independent Director
Independent Director
137.37K
+72.22%
Dr. Ingmar Bruns, M.D.
Dr. Ingmar Bruns, M.D.
Chief Medical Officer
Chief Medical Officer
36.63K
--
Ms. Andrea Paul, J.D.
Ms. Andrea Paul, J.D.
Chief Legal Officer, Corporate Secretary
Chief Legal Officer, Corporate Secretary
31.98K
-96.55%
Dr. Luke Walker, M.D.
Dr. Luke Walker, M.D.
Independent Director
Independent Director
--
--
Mr. Karan S. Takhar
Mr. Karan S. Takhar
Independent Director
Independent Director
--
--
Mr. Scott Myers
Mr. Scott Myers
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Ms. Julie Eastland
Ms. Julie Eastland
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
名稱
名稱/職務
職務
持股
持股變動
Mr. David Michael Johnson
Mr. David Michael Johnson
Independent Director
Independent Director
250.42K
+29.87%
Dr. Jan Skvarka, Ph.D.
Dr. Jan Skvarka, Ph.D.
Independent Director
Independent Director
194.95K
+41.94%
Dr. Enoch Kariuki, Pharm.D.
Dr. Enoch Kariuki, Pharm.D.
Independent Director
Independent Director
137.37K
+72.22%
Dr. Ingmar Bruns, M.D.
Dr. Ingmar Bruns, M.D.
Chief Medical Officer
Chief Medical Officer
36.63K
--
Ms. Andrea Paul, J.D.
Ms. Andrea Paul, J.D.
Chief Legal Officer, Corporate Secretary
Chief Legal Officer, Corporate Secretary
31.98K
-96.55%
Dr. Luke Walker, M.D.
Dr. Luke Walker, M.D.
Independent Director
Independent Director
--
--
收入明細
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2019
FY2018
暫無數據
地區USD
名稱
營收
佔比
United States
0.00
0.00%
業務
地區
暫無數據
股東統計
更新時間: 7月23日 週三
更新時間: 7月23日 週三
持股股東
股東類型
持股股東
持股股東
佔比
Matrix Capital Management Company, LP
19.40%
Walters (William T)
9.80%
BlackRock Institutional Trust Company, N.A.
5.33%
The Vanguard Group, Inc.
4.53%
Millennium Management LLC
4.27%
Other
56.67%
持股股東
持股股東
佔比
Matrix Capital Management Company, LP
19.40%
Walters (William T)
9.80%
BlackRock Institutional Trust Company, N.A.
5.33%
The Vanguard Group, Inc.
4.53%
Millennium Management LLC
4.27%
Other
56.67%
股東類型
持股股東
佔比
Investment Advisor/Hedge Fund
33.53%
Investment Advisor
20.08%
Hedge Fund
18.52%
Individual Investor
12.74%
Research Firm
4.62%
Venture Capital
3.66%
Corporation
1.33%
Endowment Fund
0.24%
Family Office
0.13%
Other
5.14%
機構持股
更新時間: 7月1日 週二
更新時間: 7月1日 週二
報告期間
機構數
持股數
持股佔比
持股變動
2025Q2
373
68.31M
94.93%
-22.23M
2025Q1
386
70.02M
97.36%
-19.46M
2024Q4
379
71.39M
100.17%
-15.78M
2024Q3
373
74.19M
104.47%
-21.21M
2024Q2
365
79.92M
112.67%
-23.64M
2024Q1
360
88.75M
125.22%
-9.75M
2023Q4
361
83.47M
118.17%
-13.77M
2023Q3
361
82.76M
117.68%
-11.58M
2023Q2
361
84.96M
121.10%
+6.07M
2023Q1
342
70.12M
118.05%
-6.08M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Matrix Capital Management Company, LP
13.96M
19.4%
--
--
Mar 31, 2025
Walters (William T)
7.05M
9.8%
+3.05M
+76.25%
Jan 29, 2025
BlackRock Institutional Trust Company, N.A.
3.83M
5.33%
-10.27K
-0.27%
Mar 31, 2025
The Vanguard Group, Inc.
3.26M
4.53%
-10.63K
-0.32%
Mar 31, 2025
Millennium Management LLC
3.07M
4.27%
-711.78K
-18.82%
Mar 31, 2025
Acadian Asset Management LLC
2.67M
3.72%
+1.61M
+150.56%
Mar 31, 2025
Decheng Capital LLC
2.02M
2.81%
-318.33K
-13.62%
Mar 31, 2025
Opaleye Management Inc.
1.99M
2.76%
+217.50K
+12.31%
Mar 31, 2025
Almitas Capital LLC
1.71M
2.38%
+84.03K
+5.16%
Mar 31, 2025
Tang Capital Management, LLC
1.50M
2.08%
+1.50M
--
Mar 31, 2025
查看更多
持股ETF
更新時間: 8月2日 週六
更新時間: 8月2日 週六
機構名稱
佔比
Federated Hermes MDT Small Cap Core ETF
0.07%
Invesco RAFI US 1500 Small-Mid ETF
0.01%
iShares Micro-Cap ETF
0.01%
Fidelity Enhanced Small Cap ETF
0.01%
Invesco Nasdaq Biotechnology ETF
0%
Virtus LifeSci Biotech Clinical Trials ETF
0%
Fidelity Growth Opportunities ETF
0%
T Rowe Price Small-Mid Cap ETF
0%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0%
ProShares Ultra Nasdaq Biotechnology
0%
查看更多
Federated Hermes MDT Small Cap Core ETF
佔比0.07%
Invesco RAFI US 1500 Small-Mid ETF
佔比0.01%
iShares Micro-Cap ETF
佔比0.01%
Fidelity Enhanced Small Cap ETF
佔比0.01%
Invesco Nasdaq Biotechnology ETF
佔比0%
Virtus LifeSci Biotech Clinical Trials ETF
佔比0%
Fidelity Growth Opportunities ETF
佔比0%
T Rowe Price Small-Mid Cap ETF
佔比0%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
佔比0%
ProShares Ultra Nasdaq Biotechnology
佔比0%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
